SCHEMBL1714077

SCHEMBL1714077

CC1=N/C(=C\c2c[nH]c3ncccc23)C(=O)O1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.54
HASPIN Q8TF76 4/20 0.52
SMN1; SMN2 Q16637 1/20 0.51
CHEK1 O14757 1/20 0.49
CCNT1 O60563 2/20 0.47
CDK9 P50750 2/20 0.47
CDC7 O00311 7/20 0.46
POLB P06746 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPT P10636 1/20 0.44
APEX1 P27695 1/20 0.44
RECQL P46063 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
GSK3B P49841 1/20 0.42
PIM1 P11309 1/20 0.41
PIM3 Q86V86 1/20 0.41
PIM2 Q9P1W9 1/20 0.41
MAP2K1 Q02750 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1714080 1.00 KMT2A (0.54) KMT2AHASPINSMN1; SMN2CHEK1CCNT1
SCHEMBL11471661 0.80 KDM4E (0.48) KMT2ASMN1; SMN2POLBKDM4EMAPT
SCHEMBL11471408 0.80 KDM4E (0.48) KMT2ASMN1; SMN2POLBKDM4EMAPT
SCHEMBL1713712 0.80 CHEK1 (0.55) KMT2AHASPINCHEK1CCNT1CDK9
SCHEMBL1713716 0.80 CHEK1 (0.55) KMT2AHASPINCHEK1CCNT1CDK9
SCHEMBL1713472 0.78 KMT2A (0.51) KMT2AHASPINCHEK1CCNT1CDK9
SCHEMBL1713471 0.78 KMT2A (0.51) KMT2AHASPINCHEK1CCNT1CDK9
SCHEMBL1713841 0.75 KMT2A (0.48) KMT2AHASPINCHEK1CCNT1CDK9
SCHEMBL1713843 0.75 KMT2A (0.48) KMT2AHASPINCHEK1CCNT1CDK9
SCHEMBL11463806 0.74 POLB (0.44) KMT2ASMN1; SMN2POLBKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314121-B2 Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 SANOFI (FR) 2012-11-20 US disclosed
EP-2094699-B1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI AVENTIS (FR) 2011-07-20 EP disclosed
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 CDC7, CDK7, CDK17 KMT2A 3256/4885HASPIN 583/4885SMN1; SMN2 4126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.